Percutaneous left atrial appendage occlusion: A South African experience

Background Atrial fibrillation (AF) is associated with all-cause mortality, heart failure and non-fatal stroke, and thromboprophylaxis is traditionally provided with oral anticoagulants (OACs). Percutaneous left atrial appendage occlusion (LAAO) with a dedicated device is an alternative approach to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:SAMJ: South African Medical Journal 2022-04, Vol.112 (4), p.268-272
Hauptverfasser: Dippenaar, A P, Saaiman, J A, Brink, P A, Heradien, M J, Van Der Bijl, P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 272
container_issue 4
container_start_page 268
container_title SAMJ: South African Medical Journal
container_volume 112
creator Dippenaar, A P
Saaiman, J A
Brink, P A
Heradien, M J
Van Der Bijl, P
description Background Atrial fibrillation (AF) is associated with all-cause mortality, heart failure and non-fatal stroke, and thromboprophylaxis is traditionally provided with oral anticoagulants (OACs). Percutaneous left atrial appendage occlusion (LAAO) with a dedicated device is an alternative approach to thromboprophylaxis in patients with AF who are: (i) intolerant to OACs (e.g. life-threatening haemorrhage); (ii) non-adherent to OACs; or (iii) at a high bleeding risk with OACs. Non-inferiority of LAAO compared with OACs was demonstrated in e.g. the WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) trial. Only very limited data are available on percutaneous LAAO in South Africa (SA), and no local outcome data have been reported.Objectives To compare the safety and efficacy outcomes of an SA percutaneous LAAO programme with larger international series.Methods All patients undergoing percutaneous LAAO from 2013 to 2020 at a single centre (SAEndovascular, Kuils River Netcare Hospital, SA) were included from an ongoing registry. Survival analysis was performed with the Kaplan-Meier method.Results Of 101 LAAO recipients (mean (standard deviation) age 77 (10) years, 64% male) analysed, 90 (90%) had permanent AF, 1 (1%) persistent AF and 9 (9%) paroxysmal AF. The most common indication for LAAO was previous severe bleeding (n=23; 23%). The mean device size was 23 (3) mm and the procedural success rate was 98%. After a median (interquartile range) follow-up of 21 (5 - 41) months, 6 patients (6%) experienced stroke or all-cause mortality. Four patients (4%) had a life-threatening procedural complication (tamponade n=2 (2%) and device embolisation n=2 (2%)). These outcomes are comparable to large international series, e.g. PROTECT AF.Conclusions The safety and efficacy outcomes of an SA percutaneous LAAO programme were comparable to large international series. A successful percutaneous LAAO programme is feasible in a southern African context.
doi_str_mv 10.7196/SAMJ.2022.v112i4.16077
format Article
fullrecord <record><control><sourceid>gale_sciel</sourceid><recordid>TN_cdi_scielo_journals_S0256_95742022000400007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A699491339</galeid><sabinet_id>https://hdl.handle.net/10520/ejc-m_samj_v112_i4_a268</sabinet_id><scielo_id>S0256_95742022000400007</scielo_id><sourcerecordid>A699491339</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-62b87f16d4ed6d59de2066acc369ef679fcff1fd93c2c8bde9231acaa3a059a73</originalsourceid><addsrcrecordid>eNpVkV-P1CAUxRujccfVr7BpYmJ8mRFoocW3ycZ1NGs0GX0mDFy2TGipQDf67Zduxz8TQgjwO1zOPUVxhdGmwZy922-_fN4QRMjmHmNi6w1mqGmeFCuCmnZNcUWfFitEKFtz2tQXxYsYjyjvKWfPi4uK0rZpEV0Vu28Q1JTkAH6KpQOTSpmCla6U4wiDlndQeqXcFK0f3pfbcu-n1JVbE6ySQwm_RggWBgUvi2dGugivTutl8ePmw_fr3fr268dP19vbtaoZSmtGDm1jMNM1aKYp10AQY1KpinEwrOFGGYON5pUiqj1o4KTCUklZSUS5bKrLYrO8G5UF58XRT2HIBcV-ditmt3NbEEJ1nmgWvF0EY_A_J4hJ9DYqcG7xLAhjTdNSUrcZfb2gd9KBsIPxKUg142LLOK85rir-7wdnVB4aeqv8AMbm8zPBm_8EHUiXuujdlHJL4znIFlAFH2MAI8Zgexl-C4zEHLuYYxezP7HELh5jz8Krk8fp0IP-K_uTcwZ2p67Jgx0giSghs6JLaYyi0050ctD5d_MdRpQgAUcl-sz1x8daIheThLXVA7Rmv40</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2667785248</pqid></control><display><type>article</type><title>Percutaneous left atrial appendage occlusion: A South African experience</title><source>African Journals Online (Open Access)</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Sabinet African Journals Open Access Collection</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Dippenaar, A P ; Saaiman, J A ; Brink, P A ; Heradien, M J ; Van Der Bijl, P</creator><creatorcontrib>Dippenaar, A P ; Saaiman, J A ; Brink, P A ; Heradien, M J ; Van Der Bijl, P ; Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa; Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa ; SAEndovascular, Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa ; SAEndovascular, Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa; Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</creatorcontrib><description>Background Atrial fibrillation (AF) is associated with all-cause mortality, heart failure and non-fatal stroke, and thromboprophylaxis is traditionally provided with oral anticoagulants (OACs). Percutaneous left atrial appendage occlusion (LAAO) with a dedicated device is an alternative approach to thromboprophylaxis in patients with AF who are: (i) intolerant to OACs (e.g. life-threatening haemorrhage); (ii) non-adherent to OACs; or (iii) at a high bleeding risk with OACs. Non-inferiority of LAAO compared with OACs was demonstrated in e.g. the WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) trial. Only very limited data are available on percutaneous LAAO in South Africa (SA), and no local outcome data have been reported.Objectives To compare the safety and efficacy outcomes of an SA percutaneous LAAO programme with larger international series.Methods All patients undergoing percutaneous LAAO from 2013 to 2020 at a single centre (SAEndovascular, Kuils River Netcare Hospital, SA) were included from an ongoing registry. Survival analysis was performed with the Kaplan-Meier method.Results Of 101 LAAO recipients (mean (standard deviation) age 77 (10) years, 64% male) analysed, 90 (90%) had permanent AF, 1 (1%) persistent AF and 9 (9%) paroxysmal AF. The most common indication for LAAO was previous severe bleeding (n=23; 23%). The mean device size was 23 (3) mm and the procedural success rate was 98%. After a median (interquartile range) follow-up of 21 (5 - 41) months, 6 patients (6%) experienced stroke or all-cause mortality. Four patients (4%) had a life-threatening procedural complication (tamponade n=2 (2%) and device embolisation n=2 (2%)). These outcomes are comparable to large international series, e.g. PROTECT AF.Conclusions The safety and efficacy outcomes of an SA percutaneous LAAO programme were comparable to large international series. A successful percutaneous LAAO programme is feasible in a southern African context.</description><identifier>ISSN: 0256-9574</identifier><identifier>ISSN: 2078-5135</identifier><identifier>EISSN: 2078-5135</identifier><identifier>DOI: 10.7196/SAMJ.2022.v112i4.16077</identifier><identifier>PMID: 35587805</identifier><language>eng</language><publisher>South Africa: Health and Medical Publishing Group (HMPG)</publisher><subject>Aged ; Anticoagulants - therapeutic use ; Atrial Appendage - surgery ; Atrial fibrillation ; Atrial Fibrillation - complications ; Atrial Fibrillation - therapy ; Blood vessels ; Care and treatment ; Complications and side effects ; Female ; Health Care Sciences &amp; Services ; Health Policy &amp; Services ; Hemostatic techniques ; Humans ; Male ; Medical Ethics ; Medicine, General &amp; Internal ; Medicine, Legal ; Medicine, Research &amp; Experimental ; Methods ; Patient outcomes ; Prevention ; South Africa ; Stroke (Disease) ; Stroke - etiology ; Stroke - prevention &amp; control ; Surgery ; Treatment Outcome ; Venous Thromboembolism</subject><ispartof>SAMJ: South African Medical Journal, 2022-04, Vol.112 (4), p.268-272</ispartof><rights>COPYRIGHT 2022 Health &amp; Medical Publishing Group</rights><rights>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-9705-9396</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,860,881,27901,27902,39219</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35587805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dippenaar, A P</creatorcontrib><creatorcontrib>Saaiman, J A</creatorcontrib><creatorcontrib>Brink, P A</creatorcontrib><creatorcontrib>Heradien, M J</creatorcontrib><creatorcontrib>Van Der Bijl, P</creatorcontrib><creatorcontrib>Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa; Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</creatorcontrib><creatorcontrib>SAEndovascular, Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa</creatorcontrib><creatorcontrib>SAEndovascular, Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa; Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</creatorcontrib><title>Percutaneous left atrial appendage occlusion: A South African experience</title><title>SAMJ: South African Medical Journal</title><addtitle>S Afr Med J</addtitle><description>Background Atrial fibrillation (AF) is associated with all-cause mortality, heart failure and non-fatal stroke, and thromboprophylaxis is traditionally provided with oral anticoagulants (OACs). Percutaneous left atrial appendage occlusion (LAAO) with a dedicated device is an alternative approach to thromboprophylaxis in patients with AF who are: (i) intolerant to OACs (e.g. life-threatening haemorrhage); (ii) non-adherent to OACs; or (iii) at a high bleeding risk with OACs. Non-inferiority of LAAO compared with OACs was demonstrated in e.g. the WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) trial. Only very limited data are available on percutaneous LAAO in South Africa (SA), and no local outcome data have been reported.Objectives To compare the safety and efficacy outcomes of an SA percutaneous LAAO programme with larger international series.Methods All patients undergoing percutaneous LAAO from 2013 to 2020 at a single centre (SAEndovascular, Kuils River Netcare Hospital, SA) were included from an ongoing registry. Survival analysis was performed with the Kaplan-Meier method.Results Of 101 LAAO recipients (mean (standard deviation) age 77 (10) years, 64% male) analysed, 90 (90%) had permanent AF, 1 (1%) persistent AF and 9 (9%) paroxysmal AF. The most common indication for LAAO was previous severe bleeding (n=23; 23%). The mean device size was 23 (3) mm and the procedural success rate was 98%. After a median (interquartile range) follow-up of 21 (5 - 41) months, 6 patients (6%) experienced stroke or all-cause mortality. Four patients (4%) had a life-threatening procedural complication (tamponade n=2 (2%) and device embolisation n=2 (2%)). These outcomes are comparable to large international series, e.g. PROTECT AF.Conclusions The safety and efficacy outcomes of an SA percutaneous LAAO programme were comparable to large international series. A successful percutaneous LAAO programme is feasible in a southern African context.</description><subject>Aged</subject><subject>Anticoagulants - therapeutic use</subject><subject>Atrial Appendage - surgery</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - complications</subject><subject>Atrial Fibrillation - therapy</subject><subject>Blood vessels</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Female</subject><subject>Health Care Sciences &amp; Services</subject><subject>Health Policy &amp; Services</subject><subject>Hemostatic techniques</subject><subject>Humans</subject><subject>Male</subject><subject>Medical Ethics</subject><subject>Medicine, General &amp; Internal</subject><subject>Medicine, Legal</subject><subject>Medicine, Research &amp; Experimental</subject><subject>Methods</subject><subject>Patient outcomes</subject><subject>Prevention</subject><subject>South Africa</subject><subject>Stroke (Disease)</subject><subject>Stroke - etiology</subject><subject>Stroke - prevention &amp; control</subject><subject>Surgery</subject><subject>Treatment Outcome</subject><subject>Venous Thromboembolism</subject><issn>0256-9574</issn><issn>2078-5135</issn><issn>2078-5135</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>JRA</sourceid><sourceid>EIF</sourceid><recordid>eNpVkV-P1CAUxRujccfVr7BpYmJ8mRFoocW3ycZ1NGs0GX0mDFy2TGipQDf67Zduxz8TQgjwO1zOPUVxhdGmwZy922-_fN4QRMjmHmNi6w1mqGmeFCuCmnZNcUWfFitEKFtz2tQXxYsYjyjvKWfPi4uK0rZpEV0Vu28Q1JTkAH6KpQOTSpmCla6U4wiDlndQeqXcFK0f3pfbcu-n1JVbE6ySQwm_RggWBgUvi2dGugivTutl8ePmw_fr3fr268dP19vbtaoZSmtGDm1jMNM1aKYp10AQY1KpinEwrOFGGYON5pUiqj1o4KTCUklZSUS5bKrLYrO8G5UF58XRT2HIBcV-ditmt3NbEEJ1nmgWvF0EY_A_J4hJ9DYqcG7xLAhjTdNSUrcZfb2gd9KBsIPxKUg142LLOK85rir-7wdnVB4aeqv8AMbm8zPBm_8EHUiXuujdlHJL4znIFlAFH2MAI8Zgexl-C4zEHLuYYxezP7HELh5jz8Krk8fp0IP-K_uTcwZ2p67Jgx0giSghs6JLaYyi0050ctD5d_MdRpQgAUcl-sz1x8daIheThLXVA7Rmv40</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Dippenaar, A P</creator><creator>Saaiman, J A</creator><creator>Brink, P A</creator><creator>Heradien, M J</creator><creator>Van Der Bijl, P</creator><general>Health and Medical Publishing Group (HMPG)</general><general>Health &amp; Medical Publishing Group</general><general>South African Medical Association</general><scope>AEIZH</scope><scope>JRA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>GPN</scope><orcidid>https://orcid.org/0000-0002-9705-9396</orcidid></search><sort><creationdate>20220401</creationdate><title>Percutaneous left atrial appendage occlusion: A South African experience</title><author>Dippenaar, A P ; Saaiman, J A ; Brink, P A ; Heradien, M J ; Van Der Bijl, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-62b87f16d4ed6d59de2066acc369ef679fcff1fd93c2c8bde9231acaa3a059a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Anticoagulants - therapeutic use</topic><topic>Atrial Appendage - surgery</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - complications</topic><topic>Atrial Fibrillation - therapy</topic><topic>Blood vessels</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Female</topic><topic>Health Care Sciences &amp; Services</topic><topic>Health Policy &amp; Services</topic><topic>Hemostatic techniques</topic><topic>Humans</topic><topic>Male</topic><topic>Medical Ethics</topic><topic>Medicine, General &amp; Internal</topic><topic>Medicine, Legal</topic><topic>Medicine, Research &amp; Experimental</topic><topic>Methods</topic><topic>Patient outcomes</topic><topic>Prevention</topic><topic>South Africa</topic><topic>Stroke (Disease)</topic><topic>Stroke - etiology</topic><topic>Stroke - prevention &amp; control</topic><topic>Surgery</topic><topic>Treatment Outcome</topic><topic>Venous Thromboembolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dippenaar, A P</creatorcontrib><creatorcontrib>Saaiman, J A</creatorcontrib><creatorcontrib>Brink, P A</creatorcontrib><creatorcontrib>Heradien, M J</creatorcontrib><creatorcontrib>Van Der Bijl, P</creatorcontrib><creatorcontrib>Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa; Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</creatorcontrib><creatorcontrib>SAEndovascular, Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa</creatorcontrib><creatorcontrib>SAEndovascular, Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa; Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</creatorcontrib><collection>Sabinet:Open Access</collection><collection>Sabinet African Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SciELO</collection><jtitle>SAMJ: South African Medical Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dippenaar, A P</au><au>Saaiman, J A</au><au>Brink, P A</au><au>Heradien, M J</au><au>Van Der Bijl, P</au><aucorp>Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa; Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</aucorp><aucorp>SAEndovascular, Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa</aucorp><aucorp>SAEndovascular, Kuils River Netcare Hospital, Kuils River, Cape Town, South Africa; Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Percutaneous left atrial appendage occlusion: A South African experience</atitle><jtitle>SAMJ: South African Medical Journal</jtitle><addtitle>S Afr Med J</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>112</volume><issue>4</issue><spage>268</spage><epage>272</epage><pages>268-272</pages><issn>0256-9574</issn><issn>2078-5135</issn><eissn>2078-5135</eissn><abstract>Background Atrial fibrillation (AF) is associated with all-cause mortality, heart failure and non-fatal stroke, and thromboprophylaxis is traditionally provided with oral anticoagulants (OACs). Percutaneous left atrial appendage occlusion (LAAO) with a dedicated device is an alternative approach to thromboprophylaxis in patients with AF who are: (i) intolerant to OACs (e.g. life-threatening haemorrhage); (ii) non-adherent to OACs; or (iii) at a high bleeding risk with OACs. Non-inferiority of LAAO compared with OACs was demonstrated in e.g. the WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) trial. Only very limited data are available on percutaneous LAAO in South Africa (SA), and no local outcome data have been reported.Objectives To compare the safety and efficacy outcomes of an SA percutaneous LAAO programme with larger international series.Methods All patients undergoing percutaneous LAAO from 2013 to 2020 at a single centre (SAEndovascular, Kuils River Netcare Hospital, SA) were included from an ongoing registry. Survival analysis was performed with the Kaplan-Meier method.Results Of 101 LAAO recipients (mean (standard deviation) age 77 (10) years, 64% male) analysed, 90 (90%) had permanent AF, 1 (1%) persistent AF and 9 (9%) paroxysmal AF. The most common indication for LAAO was previous severe bleeding (n=23; 23%). The mean device size was 23 (3) mm and the procedural success rate was 98%. After a median (interquartile range) follow-up of 21 (5 - 41) months, 6 patients (6%) experienced stroke or all-cause mortality. Four patients (4%) had a life-threatening procedural complication (tamponade n=2 (2%) and device embolisation n=2 (2%)). These outcomes are comparable to large international series, e.g. PROTECT AF.Conclusions The safety and efficacy outcomes of an SA percutaneous LAAO programme were comparable to large international series. A successful percutaneous LAAO programme is feasible in a southern African context.</abstract><cop>South Africa</cop><pub>Health and Medical Publishing Group (HMPG)</pub><pmid>35587805</pmid><doi>10.7196/SAMJ.2022.v112i4.16077</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-9705-9396</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0256-9574
ispartof SAMJ: South African Medical Journal, 2022-04, Vol.112 (4), p.268-272
issn 0256-9574
2078-5135
2078-5135
language eng
recordid cdi_scielo_journals_S0256_95742022000400007
source African Journals Online (Open Access); MEDLINE; DOAJ Directory of Open Access Journals; Sabinet African Journals Open Access Collection; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Aged
Anticoagulants - therapeutic use
Atrial Appendage - surgery
Atrial fibrillation
Atrial Fibrillation - complications
Atrial Fibrillation - therapy
Blood vessels
Care and treatment
Complications and side effects
Female
Health Care Sciences & Services
Health Policy & Services
Hemostatic techniques
Humans
Male
Medical Ethics
Medicine, General & Internal
Medicine, Legal
Medicine, Research & Experimental
Methods
Patient outcomes
Prevention
South Africa
Stroke (Disease)
Stroke - etiology
Stroke - prevention & control
Surgery
Treatment Outcome
Venous Thromboembolism
title Percutaneous left atrial appendage occlusion: A South African experience
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T12%3A50%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_sciel&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Percutaneous%20left%20atrial%20appendage%20occlusion:%20A%20South%20African%20experience&rft.jtitle=SAMJ:%20South%20African%20Medical%20Journal&rft.au=Dippenaar,%20A%20P&rft.aucorp=Kuils%20River%20Netcare%20Hospital,%20Kuils%20River,%20Cape%20Town,%20South%20Africa;%20Department%20of%20Medicine,%20Faculty%20of%20Medicine%20and%20Health%20Sciences,%20Stellenbosch%20University,%20Cape%20Town,%20South%20Africa&rft.date=2022-04-01&rft.volume=112&rft.issue=4&rft.spage=268&rft.epage=272&rft.pages=268-272&rft.issn=0256-9574&rft.eissn=2078-5135&rft_id=info:doi/10.7196/SAMJ.2022.v112i4.16077&rft_dat=%3Cgale_sciel%3EA699491339%3C/gale_sciel%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2667785248&rft_id=info:pmid/35587805&rft_galeid=A699491339&rft_sabinet_id=https://hdl.handle.net/10520/ejc-m_samj_v112_i4_a268&rft_scielo_id=S0256_95742022000400007&rfr_iscdi=true